Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV.
<h4>Objectives</h4>To investigate the associations of plasma lamivudine (3TC), abacavir (ABC), emtricitabine (FTC) and tenofovir (TFV) concentrations with cognitive function in a cohort of treated people with HIV (PWH).<h4>Methods</h4>Pharmacokinetics (PK) and cognitive funct...
Saved in:
| Main Authors: | Davide De Francesco, Xinzhu Wang, Laura Dickinson, Jonathan Underwood, Emmanouil Bagkeris, Daphne S Babalis, Patrick W G Mallon, Frank A Post, Jaime H Vera, Memory Sachikonye, Ian Williams, Saye Khoo, Caroline A Sabin, Alan Winston, Marta Boffito, Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0253861&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lipidic strategy for improving bioavailability of nucleoside HIV reverse transcriptase inhibitor
by: N. S. Shastina, et al.
Published: (2011-04-01) -
Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
by: George W Rutherford, et al.
Published: (2016-01-01) -
Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study
by: A. V. Kravchenko, et al.
Published: (2018-07-01) -
Nelfinavir and Non-Nucleoside Reverse Transcriptase Inhibitor-Based Salvage Regimes in Heavily Hiv Pretreated Patients
by: Jean-Guy Baril, et al.
Published: (2003-01-01) -
Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
by: Anna Maria Geretti, et al.
Published: (2013-01-01)